A β-glucan medical beauty essence with barrier repair function

Abstract

This invention discloses a β-glucan-based medical aesthetic essence with barrier repair function, belonging to the field of cosmetic technology. The invention first encapsulates fibronectin with β-glucan, then uses a heat-sensitive membrane for secondary encapsulation, allowing for sustained release of active ingredients through heat application and increasing transepidermal absorption. β-glucan, fibronectin, and *Callicarpa nudiflora* extract work synergistically for triple anti-inflammatory repair, reducing transepidermal water loss and providing long-term repair effects.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, specifically relating to a β-glucan medical beauty essence with barrier repair function. Background Technology

[0002] A healthy skin barrier is crucial for overall skin health. Composed of the stratum corneum and the sebum film, the skin barrier serves as the outermost protective system, helping the skin resist environmental damage and preventing moisture loss and external irritants. Skin barrier damage can occur due to various factors, including seasonal changes, prolonged exposure to dry, air-conditioned environments, drastic temperature and humidity fluctuations, over-cleansing, the use of irritating cosmetics, and frequent exfoliation. Damaged skin barriers can lead to dryness, flaking, sensitivity, redness, and inflammation. Repairing the skin barrier typically refers to repairing the physical barrier, often described as the "brick wall structure," which consists of the sebum film on the skin's surface, the keratinocytes of the stratum corneum, and the tightly connected intercellular lipids. Current barrier repair products suffer from drawbacks such as long repair cycles and slow results. Therefore, this invention proposes a novel β-glucan medical aesthetic essence with barrier repair functions. Summary of the Invention

[0003] The purpose of this section is to outline some aspects of embodiments of the present invention and to briefly describe some preferred embodiments. Simplifications or omissions may be made in this section, as well as in the abstract and title of this application, to avoid obscuring the purpose of these documents; however, such simplifications or omissions should not be construed as limiting the scope of the invention.

[0004] In view of the problems of long repair cycle and insignificant effect in the above and / or existing technologies, the present invention is proposed.

[0005] Therefore, the purpose of this invention is to overcome the shortcomings of the prior art and provide a β-glucan medical beauty essence with barrier repair function.

[0006] To solve the above-mentioned technical problems, the present invention provides the following technical solution: a β-glucan medical beauty essence with barrier repair function, wherein, by mass percentage, the essence comprises: β-glucan 0.03~0.5%, fibronectin 0.01~0.1%, DMPC 1~1.5%, cholesterol 0.2~0.5%, TPGS1000 0.1~0.3%, trehalose 0.1~0.8%, sodium chloride 0.01~0.1%, Callicarpa nudiflora extract 0.5~2%, collagen 0.01~0.5%, panthenol 0.1~1%, carbomer 0.1~0.5%, arginine 0.1~0.5%, glycerin 1~10%, and the balance being sterile water.

[0007] As a preferred embodiment of the β-glucan medical aesthetic essence with barrier repair function described in this invention, wherein: by mass percentage, the essence comprises,

[0008] β-glucan 0.03~0.5%, fibronectin 0.01~0.1%, DMPC 1~1.5%, cholesterol 0.35%, TPGS1000 0.2%, trehalose 0.5%, sodium chloride 0.09%, Callicarpa nudiflora extract 0.5~2%, collagen 0.3%, panthenol 0.5%, carbomer 0.25%, arginine 0.2%, glycerol 5%, balance: sterile water.

[0009] As a preferred embodiment of the β-glucan medical beauty essence with barrier repair function described in this invention, wherein: the β-glucan is a linear polymer of repeating units composed of glucose linked by 7 β-1,3-glycosidic bonds and 2 α-1,3-glycosidic bonds.

[0010] As a preferred embodiment of the β-glucan medical beauty essence with barrier repair function described in this invention, wherein the molecular weight of the β-glucan is 10 kDa to 2000 kDa.

[0011] As a preferred embodiment of the β-glucan medical beauty essence with barrier repair function described in this invention, the mass ratio of DMPC, cholesterol, and TPGS1000 is 1~1.5∶0.35∶0.2.

[0012] As a preferred embodiment of the β-glucan medical beauty essence with barrier repair function described in this invention, the mass ratio of β-glucan, fibronectin and Naked Flower Purple Extract is 0.3:0.01~0.1:0.5~2.

[0013] Another objective of this invention is to overcome the problems of long repair cycles and insignificant effects in existing technologies, and to provide a method for preparing a β-glucan medical aesthetic essence with barrier repair function.

[0014] To solve the above-mentioned technical problems, the present invention provides the following technical solution: a method for preparing a β-glucan medical aesthetic essence with barrier repair function, the preparation method comprising the following steps:

[0015] DMPC, cholesterol, and TPGS1000 were dissolved in a solvent and rotary evaporated at 35-45°C to form a uniform film. The solvent was then removed by vacuum drying for 1-3 hours to obtain the lipid film.

[0016] Fibronectin and β-glucan were dissolved in physiological saline containing 3-6% trehalose and encapsulated once by standing at 20-30°C to obtain the FN-βG complex.

[0017] The FN-βG complex was added to the lipid membrane, heated to 30-50℃, and hydrated at 100-150 rpm for 0.5-1.5 h. After secondary encapsulation, the encapsulated liposomes were extruded from the microporous membrane to obtain temperature-sensitive liposomes.

[0018] Mix glycerin and water thoroughly and dissolve completely at 55-65℃. Then cool the mixture to 25-35℃, add the remaining ingredients, and sterilize to obtain the essence.

[0019] As a preferred embodiment of the preparation method of the β-glucan medical aesthetic essence with barrier repair function described in this invention, it includes:

[0020] DMPC, cholesterol, and TPGS1000 were dissolved in a solvent in sequence, and the mixture was rotary evaporated at 40°C to form a uniform film. The solvent was then removed by vacuum drying for 2 hours to obtain the lipid film.

[0021] Fibronectin and β-glucan were dissolved in physiological saline containing 5% trehalose and encapsulated once by standing at 25°C to obtain the FN-βG complex.

[0022] The FN-βG complex was added to the lipid membrane and hydrated at 40℃ and 120 rpm for 1 hour. After secondary encapsulation, the temperature-sensitive liposomes were obtained by extruding them from the microporous filter membrane.

[0023] Glycerin and water are mixed evenly and completely dissolved at 60°C. The mixture is then cooled to 30°C, and the remaining ingredients are added. After sterilization, the essence is obtained.

[0024] In a preferred embodiment of the preparation method of the β-glucan medical beauty essence with barrier repair function described in this invention, the solvent includes one or more of ethanol and chloroform.

[0025] As a preferred embodiment of the preparation method of the β-glucan medical beauty essence with barrier repair function described in this invention, wherein: the particle size of the temperature-sensitive liposomes is 90~110nm and the PDI < 0.15.

[0026] Another objective of this invention is to overcome the shortcomings of the prior art and provide an application method for a β-glucan medical aesthetic essence with barrier repair function, comprising applying the essence to the skin and heating it to 38~39°C to release the components.

[0027] As a preferred embodiment of the application method of the β-glucan medical beauty essence with barrier repair function described in this invention, the means of heating include one or more of the following: medical beauty equipment, rubbing the palms together to warm the skin, and applying a hot compress; wherein, the medical beauty equipment includes a radio frequency device and an ultrasonic scalpel.

[0028] Beneficial effects of this invention:

[0029] This invention first encapsulates fibronectin with β-glucan, then encapsulates it a second time using a heat-sensitive membrane. This allows for the sustained release of active ingredients through heat application, increasing transdermal absorption. The synergistic effect of β-glucan, fibronectin, and *Callicarpa nudiflora* extract provides triple anti-inflammatory repair, reducing transdermal water loss and offering long-term repair benefits. Detailed Implementation

[0030] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the examples in the specification.

[0031] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0032] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0033] Unless otherwise specified, all raw materials used in this invention are commercially available.

[0034] β-glucan is celecoxib glucan produced by Sichuan Hetai Xinguang Biotechnology Co., Ltd.

[0035] Example 1

[0036] This embodiment provides a β-glucan-based medical aesthetic serum with barrier repair function, specifically:

[0037] For the serum, the formula, by weight percentage, is as follows: β-glucan 0.3%, fibronectin (FN) 0.05%, myristoyl phosphatidylcholine (DMPC) 1.2%, cholesterol 0.35%, vitamin E polyethylene glycol succinate (TPGS1000) 0.2%, trehalose 0.5%, sodium chloride 0.09%, Callicarpa nudiflora extract 1%, collagen 0.3%, panthenol 0.5%, carbomer 0.25%, arginine 0.2%, glycerin 5%, and the balance being sterile water.

[0038] The preparation method for serum includes the following steps:

[0039] DMPC, cholesterol, and TPGS1000 were sequentially dissolved in a solvent, which was a mixture of ethanol and chloroform with a volume ratio of 9:1. The mixture was rotary evaporated at 40°C to form a uniform film, and then vacuum dried for 2 hours to remove the solvent, thus obtaining the lipid film.

[0040] Fibronectin and β-glucan were dissolved in physiological saline containing trehalose and encapsulated once by standing at 25°C to obtain the FN-βG complex.

[0041] The FN-βG complex was added to the lipid membrane and hydrated at 40℃ and 120 rpm for 1 hour. After secondary encapsulation, the encapsulated liposomes with a particle size of 90~110 nm were obtained by extruding them from the microporous filter membrane.

[0042] Glycerin and water are mixed evenly and completely dissolved at 60°C. The mixture is then cooled to 30°C, and temperature-sensitive liposomes, Naked Flower Purple Extract, collagen, panthenol carbomer, and arginine are added. After sterilization, the essence is obtained.

[0043] Example 2

[0044] The difference between this embodiment and Example 1 is that the amount of fibronectin added in the formula is adjusted to 0.01%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0045] Example 3

[0046] The difference between this embodiment and Example 1 is that the amount of fibronectin added in the formula is adjusted to 0.1%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0047] Comparative Example 1

[0048] The difference between this comparative example and Example 1 is that the amount of fibronectin added in the formula is adjusted to 0, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0049] Comparative Example 2

[0050] The difference between this comparative example and Example 1 is that the amount of fibronectin added in the formula was adjusted to 0.5%, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0051] Example 4

[0052] The difference between this embodiment and Example 1 is that the amount of Callicarpa nudiflora extract added to the formula is adjusted to 0.5%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0053] Example 5

[0054] The difference between this embodiment and Example 1 is that the amount of Callicarpa nudiflora extract added to the formula is adjusted to 2%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0055] Comparative Example 3

[0056] The difference between this comparative example and Example 1 is that the amount of Callicarpa nudiflora extract added to the formula was adjusted to 0, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0057] Comparative Example 4

[0058] The difference between this comparative example and Example 1 is that the amount of Callicarpa nudiflora extract added to the formula was adjusted to 0.25%, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0059] Comparative Example 5

[0060] The difference between this comparative example and Example 1 is that the amount of Callicarpa nudiflora extract added to the formula was adjusted to 3%, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0061] Example 6

[0062] The difference between this embodiment and Example 1 is that the amount of DMPC added in the formula is adjusted to 1%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0063] Example 7

[0064] The difference between this embodiment and Example 1 is that the amount of DMPC added in the formula is adjusted to 1.5%, while the rest of the preparation process is the same as in Example 1, and the essence is obtained.

[0065] Comparative Example 6

[0066] The difference between this comparative example and Example 1 is that the amount of DMPC added in the formula was adjusted to 0.5%, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0067] Comparative Example 7

[0068] The difference between this comparative example and Example 1 is that the amount of DMPC added in the formula was adjusted to 2%, while the rest of the preparation process was the same as in Example 1, and the essence was obtained.

[0069] Comparative Example 8

[0070] The difference between this comparative example and Example 1 is that the preparation method is adjusted so that all raw materials are mixed sequentially without encapsulation to obtain the essence.

[0071] Comparative Example 9

[0072] The difference between this comparative example and Example 1 is that the addition amounts of β-glucan, fibronectin, and Naked Flower Purple Extract in the formula were all adjusted to 0, while the rest of the preparation process was the same as in Example 1, resulting in an essence.

[0073] 1) The serum prepared in the above examples was subjected to a keratinocyte toxicity test as follows:

[0074] Keratinocyte suspensions were seeded into 96-well plates at a density of 8 × 10⁶ cells / well. 3 Cells were cultured in 37 ℃, 5% CO2 incubator for 24 h. The extract prepared in the above example was added to each well, while the control group was added with normal culture medium. After culturing for 24 h and 48 h, the supernatant was discarded, the cells were washed once with PBS, and 100 μL of medium containing 10% CCK8 was added to each well. The cells were then incubated in a 37 ℃ constant temperature incubator for 2 h with 5% CO2, and the absorbance at 450 nm was measured. After subtracting the background absorbance from the absorbance values ​​of each group, the cell viability of each concentration group was calculated with the absorbance value of the cell control group as 100%. The calculation formula is as follows:

[0075] Cell viability = (sample well absorbance / control group absorbance) × 100%.

[0076] The test results are shown in the table below:

[0077] Table 1

[0078] control group Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Cell viability (%) 100 115 102 104 99 98 101 85

[0079] As can be seen from the table above, the essence prepared by this invention did not show obvious cytotoxicity to keratinocytes.

[0080] 2) The serum prepared in the above examples was subjected to a skin barrier repair test for tape peel damage using the following method:

[0081] Subjects were selected who had not recently used any medications, had no history of skin diseases, and whose test areas were free of large-area birthmarks, scratches, vitiligo, pigmented nevi, keloids, or other skin abnormalities that might affect the test results. The test was conducted in an indoor temperature of 20–22°C and a relative humidity of 40–60%.

[0082] A 2cm × 2cm test area was randomly marked on the inner forearm of the subject, serving as both the blank test area and the experimental test area, with a minimum 1cm interval between the test areas. Data from transdermal water loss measurement were used as baseline values.

[0083] Adhesive tape was repeatedly peeled 20 times in both the blank test area and the experimental test area to simulate skin barrier damage. Data was measured immediately after peeling. No sample was used in the blank test area, while the experimental test area was uniformly coated with test sample and then subjected to a 39°C heat compress. Transdermal water loss (TEWL) data were measured again 4 and 6 hours later. The results of the transdermal water loss (TEWL) test are shown in the table below:

[0084] Table 2

[0085] <![CDATA[Base value g / (cm 2 ·h)]]> <![CDATA[Instantaneous damage g / (cm 2 ·h)]]> <![CDATA[4 h after use g / (cm 2 ·h)]]> <![CDATA[6 h after use, g / (cm 2 ·h)]]> Blank group 8.39 18.97 14.98 14.67 Example 1 8.49 17.36 11.66 10.87 Example 2 8.75 17.57 12.5 12.16 Example 3 8.25 18.25 12.65 12.46 Example 4 8.87 18.71 13.75 12.72 Example 5 8.06 18.58 12.68 12.27 Example 6 8.80 17.7 13.12 12.84 Example 7 8.36 18.29 12.36 12.22 Comparative Example 1 8.71 18.77 14.73 14.01 Comparative Example 2 8.01 18.51 14.48 14.46 Comparative Example 3 8.85 18.14 14.38 14.36 Comparative Example 4 8.24 17.61 14.29 14.1 Comparative Example 5 8.05 17.79 13.61 13.19 Comparative Example 6 8.47 18.11 14.44 14.16 Comparative Example 7 8.74 18.93 14.68 14.67 Comparative Example 8 8.52 17.18 14.06 13.43 Comparative Example 9 8.68 18.47 13.93 13.54

[0086] As shown in the table above, the baseline TEWL value of the subjects was 8.39 g / (cm³). 2 • h). After tape peeling damage, the TEWL in the blank group increased to 18.97 g / (cm). 2 The results (·h) indicate that the skin barrier was damaged after the tape was peeled off. After 4 and 6 hours of using the serum prepared in this embodiment of the invention, the TEWL value continued to decrease. Specifically, the TEWL value reduction rate of the serum in Example 1 after 4 and 6 hours of use was 56.11% and 64.93% higher than that of the control group, respectively. The TEWL values ​​in the test area improved after 4 and 6 hours of use compared to the immediate values ​​after peeling damage, and the change rate was greater than that in the control area. This indicates that the serum prepared in this embodiment of the invention has a skin barrier repairing effect after use.

[0087] 3) The essence prepared in this embodiment of the invention was subjected to a human facial barrier damage openness test using the following method:

[0088] The trial employed a self-controlled pre- and post-treatment approach. After obtaining informed consent, volunteers were selected using the same selection criteria as the adhesive tape peel damage skin barrier repair test. Volunteers cleansed their faces and waited for at least 20 minutes in a constant temperature and humidity environment. Facial skin moisture content and transepidermal water loss were measured as initial values. Volunteers with damaged skin barriers were then selected as subjects. Subjects received and used the sample at home continuously for 14 and 28 days as instructed, and the results are shown in the table below:

[0089] Table 3

[0090]

[0091] As can be seen from the table above, the TEWL of facial skin is >15g / (cm³). 2 •h) is generally considered to be barrier-damaged skin, therefore, initial TEWL >15 g / (cm) was selected. 2Volunteers (h) were enrolled. Compared to the control group, the transepidermal water loss (TEWL) of the group using the serum prepared according to this invention was significantly reduced, and the skin moisture content was significantly increased. Compared with the initial values, after 14 days of use, the TEWL value decreased by 21.50–31.82%, and the skin stratum corneum moisture content increased by 27.89–33.22%. Continued improvement was observed after 28 days of use, with the TEWL value decreasing by a maximum of 35.79% and the skin stratum corneum moisture content increasing by 34.18%. This indicates that the serum prepared according to this invention has a long-term repair effect.

[0092] In summary, this invention first encapsulates fibronectin with β-glucan, then encapsulates it a second time using a heat-sensitive membrane. This allows for the sustained release of active ingredients through heat application, increasing transdermal absorption. The synergistic effect of β-glucan, fibronectin, and *Callicarpa nudiflora* extract provides triple anti-inflammatory repair, reducing transdermal water loss and offering long-term repair benefits.

[0093] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.

Claims

1. A β-glucan medical beauty serum having a barrier repair function, characterized by: The serum includes, in percentage by mass, Beta-glucan 0.3%, fibronectin 0.05%, DMPC 1.2%, cholesterol 0.35%, TPGS1000 0.2%, trehalose 0.5%, sodium chloride 0.09%, Ligustrum robustum extract 1%, collagen 0.3%, panthenol 0.5%, carbomer 0.25%, arginine 0.2%, glycerol 5%, and the balance being sterile water; The preparation method of the beta-glucan medical and cosmetic serum with barrier repair function includes, DMPC, cholesterol and TPGS1000 are dissolved in a solvent, rotary evaporation into a uniform film, vacuum drying to remove the solvent, and a lipid film is obtained; Fibronectin and beta-glucan are dissolved in physiological saline containing trehalose, and a first wrapping is performed by standing, to obtain an FN-betaG complex; The FN-betaG complex is added to the lipid film, heated and stirred to hydrate, and a second wrapping is performed, and after the wrapping is completed, it is extruded from a microporous filter membrane to obtain a temperature-sensitive liposome; Glycerol and water are mixed uniformly, completely dissolved, cooled, the remaining ingredients are added, sterilized, and the serum is obtained. The serum is warmed to 38-39℃ to achieve slow release of active ingredients.

2. The β-glucan medical essence having barrier repair function according to claim 1, wherein: The beta-glucan is a linear polymer of repeating units of glucose connected by 7 beta-1,3-glycosidic bonds and 2 alpha-1,3-glycosidic bonds.

3. The β-glucan medical essence having a barrier repair function according to claim 1 or 2, characterized by: The molecular weight of the beta-glucan is 10 kDa-2000 kDa.

4. The β-glucan medical essence having barrier repair function according to claim 1, wherein: The solvent includes one or more of ethanol, chloroform; the rotary evaporation temperature is 35-45℃; the vacuum drying time is 1-3h.

5. The β-glucan medical aesthetic essence with barrier repair function as described in claim 1, characterized in that: The first wrapping temperature is 20-30℃; the content of trehalose in the physiological saline is 3-6%.

6. The β-glucan medical essence having barrier repair function according to claim 1, wherein: The hydration, wherein the temperature is 30-50℃, the rotation speed is 100-150rpm, and the time is 0.5-1.5h; the particle size of the temperature-sensitive liposome is 90-110nm, and PDI<0.15; the glycerol and water are mixed uniformly, and the complete dissolution temperature is 55-65℃, and the cooling temperature is 25-35℃.

Images